Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650104 · ClinicalTrials.gov registry record · Phase 3
Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 76
- Enrollment target
NCT00650104 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 76 participants.
The verdict
NCT00650104, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study is to obtain information on the long-term safety, tolerability, and therapeutic benefit of extended release ropinirole XL, and to provide a mechanism for patients who participated in either Study 167 or Study 164 to continue receiving ropinirole XL if they chose to do so.
Interventions
- DRUG Ropinirole XL (formerly CR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2002-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650104
The ClinicalTrials.gov registry entry for NCT00650104 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ropinirole XL (formerly CR) is the first listed.
NCT00650104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650104 about?
NCT00650104 is a clinical study titled "Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164". The purpose of this study is to obtain information on the long-term safety, tolerability, and therapeutic benefit of extended release ropinirole XL, and to provide a mechanism for patients who participated in either Study 167 or Study 164 to continue receiving ropinirole XL if they chose to do so.
What is the current status of trial NCT00650104?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 76 participants. The study started on 2002-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00650104?
The interventions under investigation include: Ropinirole XL (formerly CR) (DRUG).
Who is sponsoring clinical trial NCT00650104?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.